Fut, nem toboroz2. fázis
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
A legfontosabb adatok
- Ki végzi
- GlaxoSmithKline
- Hol
- Austin, Binghamton, Birmingham, Charleston, Charlotte, Endwell, Galveston, Grand Island, Gresham, Haughton, Kingsport, Layton, Lincoln, Macon, Miami, Missoula, Nicholasville, Omaha, Tucson, Valparaiso, Ventura és Washington D.C. (Egyesült Államok)Mind a 22 helyszín megnézéseMég 1 másik országban, 6 helyszínen
- Állapot
- Fut, nem toboroz
- Fázis
- 2. fázis
- Résztvevők
- 305 fő vett részt
- Kezdés
- 2021. nov. 18.
- Várható befejezés
- 2027. márc. 10.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- MenABCWY vaccine
- Placebo
- A regiszteradat frissítve
- 2026. szeptember 28.
Ki vehet részt
- Életkor
- 11 év – 14 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Participants or/and participants' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol
- Written or witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study specific procedure
- Written informed assent obtained from the participant (if applicable) prior to performing any study specific procedure
- A male or female between, and including, 11 and 14 years of age (i.e. 14 years + 364 days) at the time of the first vaccination
- Healthy participants as established by medical history, physical examination and clinical judgment of the investigator before entering into the study
- Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral-salpingectomy or bilateral ovariectomy
- Female participants of childbearing potential may be enrolled in the study, if the participant:; has practiced adequate contraception for 30 days prior to first vaccination, and; has a negative pregnancy test* on the day of vaccination, and; has agreed to follow adequate contraception for 30 days before each of the 2 subsequent vaccinations and for 30 days after each vaccination * Urine samples for pregnancy testing will be collected from female participants of childbearing potential at Visit 1, Visit 3 and Visit 5 prior to the vaccination
Ki nem vehet részt
- Current or previous, confirmed or suspected disease caused by N. meningitidis
- Abnormal function or modification of the immune system resulting from:; Autoimmune disorders or immunodeficiency syndromes; Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to study vaccination. This will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed; Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination; Administration of long-acting immune-modifying drugs at any time during the study period
- Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study; Prior/Concomitant therapy
- Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study vaccine(s)/product(s) during the period starting 30 days before the first dose of study vaccine(s)/product(s) (Day -29 to Day 1), or planned use during the study period
- Previous vaccination with any meningococcal (MenB or MenACWY) vaccine at any time prior to informed consent/ assent (as applicable) with the exception of meningococcal C (conjugated or polysaccharide) vaccination, if the last dose of MenC was received at ≤24 months of age
- Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of study vaccine/product or planned administration before the next blood sampling visit
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine/product dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed; Prior/Concurrent clinical study experience
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device); Other exclusions
- Medical conditions
- Progressive, unstable or uncontrolled clinical conditions
- Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
- Any neuroinflammatory, congenital neurological conditions, encephalopathies, seizures. History of febrile convulsions should not lead to exclusion
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s)/product(s); Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM197) and latex medicinal products or medical equipment whose use is foreseen in this study
- History of /current chronic alcohol abuse and/or drug abuse as determined by the investigator
- Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment
- Child in care
- Pregnant or lactating female
- Female planning to become pregnant / planning to discontinue contraceptive precautions during the windows reported in the inclusion criterion
- Any study personnel or immediate dependants, family, or household members
Helyszínek itt: Egyesült Államok
Még 1 másik országban, 6 helyszínen
- Austin, TexasHospital not named in the registry
- Binghamton, New YorkHospital not named in the registry
- Birmingham, AlabamaHospital not named in the registry
- Charleston, South CarolinaHospital not named in the registry
- Charlotte, North CarolinaHospital not named in the registry
- Endwell, New YorkHospital not named in the registry
- Galveston, TexasHospital not named in the registry
- Grand Island, NebraskaHospital not named in the registry
- Gresham, OregonHospital not named in the registry
- Haughton, LouisianaHospital not named in the registry
- Kingsport, TennesseeHospital not named in the registry
- Layton, UtahHospital not named in the registry
- Lincoln, NebraskaHospital not named in the registry
- Macon, GeorgiaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Missoula, MontanaHospital not named in the registry
- Nicholasville, KentuckyHospital not named in the registry
- Omaha, NebraskaHospital not named in the registry
- Tucson, ArizonaHospital not named in the registry
- Valparaiso, IndianaHospital not named in the registry
- Ventura, CaliforniaHospital not named in the registry
- Washington D.C., District of ColumbiaHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
A vizsgálat 2 csoportja
- ABCWY-24 GroupA vizsgált kezelés
Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 721, 1 dose of Placebo at Day 1441.
Kezelés: MenABCWY vaccine és Placebo
- ABCWY-48 GroupA vizsgált kezelés
Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 1441, 1 dose of Placebo at Day 721.
Kezelés: MenABCWY vaccine és Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
- A regiszteradat frissítve
- 2026. szeptember 28.